What Is PT-141? Benefits, Research & Safety

PT-141 emerged from research into Melanotan II at the University of Arizona. During clinical trials of Melanotan II for tanning, researchers observed significant effects on sexual function, including spontaneous erections in men and increased arousal in women. Recognizing the therapeutic potential, Palatin Technologies acquired rights to develop a derivative specifically targeting sexual dysfunction. PT-141 was designed as a metabolite of Melanotan II with reduced pigmentation effects but retained activity at melanocortin receptors involved in sexual function. Clinical development proceeded through multiple trials for both male erectile dysfunction and female sexual dysfunction. Initial development for ED was complicated by blood pressure effects observed with intravenous and intranasal administration. The focus shifted to female hypoactive sexual desire disorder, where subcutaneous administration showed efficacy with an acceptable safety profile. Phase III trials (RECONNECT studies) demonstrated statistically significant improvements in desire and reduction in distress. In 2019, the FDA approved bremelanotide (Vyleesi) for HSDD in premenopausal women, making it the first centrally-acting treatment for this condition. The approval came with a boxed warning regarding nausea and blood pressure effects. Research continues into potential applications including male sexual dysfunction, though no additional approvals have been granted.